Clinical Trials Browser

INDUSTRY × simtuzumab × Gastrointestinal × Clear all

NCT01479465 2019-04-17

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Phase 2 Terminated

266 enrolled 15 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01472198 2015-03-10

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Phase 2 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms